A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

For Phase Ib It aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect, immunogenicity in subjects with relapsed/ refractory Multiple Myeloma, and determine the recommended Phase 2 dose of GC012F (AZD0120).

For Phase 2, it aims to evaluate the efficacy, to further characterize the safety of GC012F (AZD0120), pharmacodynamic effect, and immunogenicity, changes from baseline for subject-reported health-related quality of life, overall health status in subjects with relapsed/ refractory Multiple Myeloma.

Sponsor

AstraZeneca

Status of enrollment

Recruiting

Ages Eligible for Study

Adults aged 18 years and up

Genders Eligible for Study

Males or Females

Disease indication

Relapsed and/or Refractory Multiple Myeloma

Principal Investigator

Anupama Kumar, MD

Contact

 
[email protected] 
 

 

Additional study eligibility details can be found at UCSF Clinical Trials.